In order to develop a more tailored approach to evaluating drugs and biologics for rare diseases, the US Food and Drug Administration (FDA) has launched a new initiative.
Announced on October 14 by the US Department of Health and Human Services (HHS), the Rare Disease Framework Initiative seeks to create